OTCM
ETXPF
Market cap81mUSD
Apr 16, Last price
0.13USD
Name
E-Therapeutics PLC
Chart & Performance
P/E
—
P/S
188.46
EPS
—
Div Yield, %
—
Shrs. gr., 5y
12.71%
Rev. gr., 5y
239.12%
Revenues
318k
-33.05%
Net income
-11m
L+34.95%
CFO
-11m
L+36.03%
Profile
e-Therapeutics plc engages in drug discovery research activities in the United Kingdom. Its computational platform provides in silico screens generate predictions on compounds and/or targets that can have a significant perturbative effect on the biology of interest, captured by its network models, as well as developing RNAi platform for highly specific gene silencing. The company was incorporated in 2001 and is based in London, the United Kingdom.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY |
|---|---|---|
| 2024‑01 | 2023‑01 | |
| Income | ||
Revenues | 318 -33.05% | 475 |
Cost of revenue | 14,112 | 12,390 |
Unusual Expense (Income) | ||
NOPBT | (13,794) | (11,915) |
NOPBT Margin | ||
Operating Taxes | 1,915 | (1,846) |
Tax Rate | ||
NOPAT | (15,709) | (10,069) |
Net income | (11,166) 34.95% | (8,274) |
Dividends | ||
Dividend yield | ||
Proceeds from repurchase of equity | 13,437 | |
BB yield | -15.53% | |
| Debt | ||
Debt current | 393 | 295 |
Long-term debt | 1,027 | 295 |
Deferred revenue | ||
Other long-term liabilities | ||
Net debt | (19,245) | (31,099) |
| Cash flow | ||
Cash from operating activities | (10,897) | (8,011) |
CAPEX | (247) | (68) |
Cash from investing activities | 232 | 18,284 |
Cash from financing activities | (359) | 13,046 |
FCF | (16,082) | |
| Balance | ||
Cash | 20,665 | 31,689 |
Long term investments | ||
Excess cash | 20,649 | 31,665 |
Stockholders' equity | (90,655) | (79,569) |
Invested Capital | 113,358 | 112,538 |
ROIC | ||
ROCE | ||
| EV | ||
Common stock shares outstanding | 584,335 | 537,346 |
Price | 0.18 12.61% | 0.16 |
Market cap | 105,940 22.46% | 86,513 |
EV | 86,695 | 55,414 |
EBITDA | (13,321) | (11,447) |
EV/EBITDA | ||
Interest | 23 | |
Interest/NOPBT | ||